stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Shares outstanding
Lakefront Biotherapeutics - Sponsored ADR's shares outstanding at the end of fiscal 2025 was $65.9M, unchanged from fiscal 2024. At the end of the quarter to 31 March 2026 it was $65.9M. Over the past ten years it has ranged from $35.7M (fiscal 2015) to $65.9M (fiscal 2024); the current reading is higher than 82% of that period. Lakefront Biotherapeutics - Sponsored ADR ranks 232nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $65.9M | (0.07%) |
| FY2024 | $65.9M | 0.01% |
| FY2023 | $65.9M | 0.36% |
| FY2022 | $65.7M | 0.30% |
| FY2021 | $65.5M | 0.65% |
| FY2020 | $65.1M | 8.26% |
| FY2019 | $60.1M | 15.35% |
| FY2018 | $52.1M | 5.32% |
| FY2017 | $49.5M | 4.59% |
| FY2016 | $47.3M | 32.52% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Mar 2026 | $65.9M | 0.06% |
| Mar 2025 | $65.8M | (0.04%) |
| Mar 2024 | $65.9M | (0.07%) |
| Sep 2023 | $65.9M | 0.00% |
| 28 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| ZYME Zymeworks Inc. compare | $73.0M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $65.9M |
| VCEL Vericel Corporation compare | $53.0M |
| SEPN Septerna, Inc. compare | $45.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement